For its 13th edition, BioFIT is proud to be sponsored by GENFIT, a long-time partner of the event. GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterised by high unmet medical needs.
Pascal Prigent, CEO of GENFIT commented:
“As a biotechnology company headquartered in the Health Cluster Eurasanté for years, we believe that creating strong connections with our health-innovation ecosystem is essential and mutually beneficial.”
In 2024, GENFIT achieved a historic milestone with the marketing authorization of elafibranor in the US, a “first-in-class” product developed in-house, all the way from discovery to the conclusion of a pivotal Phase III study. The product is now marketed and commercialized in the US by Ipsen under the trademark IQIRVO®.
Today, GENFIT focuses on ACLF, or Acute On-Chronic Liver Failure, a life-threatening condition for which there is currently no therapeutic solution. ACLF presents as a syndrome defined by a cascade of hepatic and extrahepatic organ dysfunctions and failures. In patients with liver cirrhosis and acute hepatic decompensation, ACLF can be triggered by a precipitating event that leads to a progressive functional deterioration of multiple organs with high short-term mortality.
Five different programs are now being conducted with the hope to meet the medical demand for patients in needs.
With such an advancement in their field and an example to follow in terms of innovation in the biotech sector, BioFIT is honoured to be sponsored by GENFIT and will be keen to follow their progress.
